<?xml version='1.0' encoding='utf-8'?>
<document id="26969417"><sentence text="Single-Dose Interaction Study of the Arginine Vasopressin Type 1B Receptor Antagonist ABT-436 and Alcohol in Moderate Alcohol Drinkers."><entity charOffset="98-105" id="DDI-PubMed.26969417.s1.e0" text="Alcohol" /><entity charOffset="118-125" id="DDI-PubMed.26969417.s1.e1" text="Alcohol" /><pair ddi="false" e1="DDI-PubMed.26969417.s1.e0" e2="DDI-PubMed.26969417.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26969417.s1.e0" e2="DDI-PubMed.26969417.s1.e1" /></sentence><sentence text="ABT-436, a potent and selective arginine vasopressin (AVP) type 1B receptor (V1B ) antagonist, has previously demonstrated basal hypothalamic-pituitary-adrenal (HPA) axis attenuation in man"><entity charOffset="32-40" id="DDI-PubMed.26969417.s2.e0" text="arginine" /><entity charOffset="41-52" id="DDI-PubMed.26969417.s2.e1" text="vasopressin" /><entity charOffset="54-57" id="DDI-PubMed.26969417.s2.e2" text="AVP" /><pair ddi="false" e1="DDI-PubMed.26969417.s2.e0" e2="DDI-PubMed.26969417.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26969417.s2.e0" e2="DDI-PubMed.26969417.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26969417.s2.e0" e2="DDI-PubMed.26969417.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26969417.s2.e1" e2="DDI-PubMed.26969417.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26969417.s2.e1" e2="DDI-PubMed.26969417.s2.e2" /></sentence><sentence text=" A V1B antagonist is hypothesized as an alcohol-dependent treatment based on the role of the V1B receptor in stress regulation and the finding that stress is a trigger for relapse in alcoholics"><entity charOffset="40-47" id="DDI-PubMed.26969417.s3.e0" text="alcohol" /></sentence><sentence text=" A V1B antagonist has shown favorable effects in rat models of alcohol dependence"><entity charOffset="63-70" id="DDI-PubMed.26969417.s4.e0" text="alcohol" /></sentence><sentence text=" A single-dose clinical study was conducted to assess the potential for pharmacokinetic or pharmacodynamic interaction between ABT-436 and alcohol"><entity charOffset="139-146" id="DDI-PubMed.26969417.s5.e0" text="alcohol" /></sentence><sentence text="" /><sentence text="Twenty moderate alcohol drinkers each received the 4 possible combinations of a single 1,000 mg ABT-436 dose (or matching placebo) and a single 0"><entity charOffset="16-23" id="DDI-PubMed.26969417.s7.e0" text="alcohol" /></sentence><sentence text="5 g/kg alcohol dose (or placebo for alcohol) in a double-blind, randomized, 4-period crossover study"><entity charOffset="7-14" id="DDI-PubMed.26969417.s8.e0" text="alcohol" /><entity charOffset="36-43" id="DDI-PubMed.26969417.s8.e1" text="alcohol" /><pair ddi="false" e1="DDI-PubMed.26969417.s8.e0" e2="DDI-PubMed.26969417.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26969417.s8.e0" e2="DDI-PubMed.26969417.s8.e1" /></sentence><sentence text=" Plasma ABT-436 and blood alcohol levels were measured to assess pharmacokinetic interactions"><entity charOffset="26-33" id="DDI-PubMed.26969417.s9.e0" text="alcohol" /></sentence><sentence text=" A computerized cognitive test battery (CDR System), Bond-Lader Visual Analog Scales scales, and a postural stability test were used to measure the effects of alcohol and the potential interaction with ABT-436"><entity charOffset="159-166" id="DDI-PubMed.26969417.s10.e0" text="alcohol" /></sentence><sentence text=" The pharmacologic effect of ABT-436 was assessed by measuring serum cortisol" /><sentence text="" /><sentence text="Neither ABT-436 nor alcohol affected the blood levels of the other"><entity charOffset="20-27" id="DDI-PubMed.26969417.s13.e0" text="alcohol" /></sentence><sentence text=" Alcohol reduced performance on 2 of 5 CDR System composite variables (power of attention, p = 0"><entity charOffset="1-8" id="DDI-PubMed.26969417.s14.e0" text="Alcohol" /></sentence><sentence text="002; quality of secondary episodic memory, p &lt; 0" /><sentence text="001), and decreased postural stability (p = 0" /><sentence text="043)" /><sentence text=" ABT-436 did not exacerbate those deleterious effects" /><sentence text=" ABT-436 reduced serum cortisol (p &lt; 0"><entity charOffset="23-31" id="DDI-PubMed.26969417.s19.e0" text="cortisol" /></sentence><sentence text="001), and alcohol did not significantly diminish this expected effect on the HPA axis"><entity charOffset="10-17" id="DDI-PubMed.26969417.s20.e0" text="alcohol" /></sentence><sentence text="" /><sentence text="No pharmacokinetic or pharmacodynamic interaction between ABT-436 and alcohol was observed"><entity charOffset="70-77" id="DDI-PubMed.26969417.s22.e0" text="alcohol" /></sentence><sentence text="" /></document>